Avotres

Avotres Inc. is a private biotechnology company developing therapies for incurable immunologically mediated disorders by targeting the root cause of lost self-tolerance. Its lead asset, AVT001, is a cell therapy that acts on the Qa-1/HLA-E restricted CD8+ regulatory T cell pathway and has completed a double-blind, placebo-controlled Phase I/II trial in the United States for Type 1 Diabetes. The pipeline also includes a multiple-sclerosis program advancing toward Phase IIb, transplant-rejection work, monoclonal antibody AVT002 for immuno-oncology, and diagnostic candidate AVT-Dx 001.